LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce…

Click here to view the original article.